8 800 700-19-93 hotline about product AVZ
8 800 770-73-03 По заказам из интернет-магазина

Hepasafe solution for injections

10 ml
Application :

Used in various hepatic diseases

Release form :

Hepasafe is manufactured in 10 ml amber glass bottles individually packed in cartons with a package insert.

Product benefits:

  • Provides regenerative, antioxidant properties and promotes intoxication removal.
  • Nonredundant strong hepatoprotector in chemotherapy.
  • Convenient dosage.

Chemical composition and pharmacological properties

Hepasafe is a hepatotrophic drug.
1 ml contains silymarin - 12 mg and vitamin E - 2 mg (as active ingredients), as well as excipients.
The drug contains complex of isomeric bioflavonoids (flavolignans including silibinin, silicristin, silydianin, isosilibinin and dehydrosilibinin) derived from medicinal herb of holy thistle (Silybum marianum (L.)), as well as essential phospholipids and vitamins.
Holy thistle flavolignans are strong antioxidants inactivating both free radicals and active cellular oxygen, blocking receptors and transportation systems on cellular membrane (which are responsible for transmission of toxic substances to the cell), reducing macrophage cell activity (which participates in antigen presentation), decreasing gamma globulin production, blocking lipoxygenases and cyclooxygenases, thus providing immunomodulatory and anticarcinogenic effect.


Hepasafe is intended for complex treatment and prevention of various acute and chronic hepatic diseases including infectious and invaded ones, toxic hepatic affections; for reduction of adverse events in administration of hepatotoxic chemotherapeutic agents; it is also used in dystrophy, fatty liver infiltration and lipid storage disease correction in dogs and cats.


Increased individual sensitivity to the drug components.

Dosage and administration

Once a day administer intramuscularly (both in dogs and cats) in dose of 0.1 ml per 1 kg of body weight (1.2 mg of silymarin and 0.2 mg of vitamin E per 1 kg of body weight). Treatment course duration is 7-14 days depending on pathological behavior.
Prevention: administer the drug in a single dose (0.1 ml per 1 kg of body weight).

Adverse events

Adverse events and complications are generally not observed in case of administration as per package insert. In case of increased individual sensitivity to the drug and allergic reactions, stop administration and use antihistaminic and symptomatic drugs (if appropriate).


Store Hepasafe in closed original package. Protect from light and moisture. Store separately from food and animal feeding at 2-25°С.
Shelf life is 1 year from manufacturing date when stored in accordance with regulations. After the first bottle opening store the drug at 2-10°С up to 10 days.
Do not use after shelf life termination.

Pharmaceutical form

Hepasafe is manufactured in 10 ml amber glass bottles individually packed in cartons with a package insert.